Your browser doesn't support javascript.
loading
Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.
Martin, Thomas; Usmani, Saad Z; Berdeja, Jesus G; Agha, Mounzer; Cohen, Adam D; Hari, Parameswaran; Avigan, David; Deol, Abhinav; Htut, Myo; Lesokhin, Alexander; Munshi, Nikhil C; O'Donnell, Elizabeth; Stewart, A Keith; Schecter, Jordan M; Goldberg, Jenna D; Jackson, Carolyn C; Yeh, Tzu-Min; Banerjee, Arnob; Allred, Alicia; Zudaire, Enrique; Deraedt, William; Olyslager, Yunsi; Zhou, Changwei; Pacaud, Lida; Madduri, Deepu; Jakubowiak, Andrzej; Lin, Yi; Jagannath, Sundar.
Afiliación
  • Martin T; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA.
  • Usmani SZ; Memorial Sloan Kettering Cancer Center, New York, NY.
  • Berdeja JG; Sarah Cannon Research Institute, Nashville, TN.
  • Agha M; UPMC Hillman Cancer Center, Pittsburgh, PA.
  • Cohen AD; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
  • Hari P; Medical College of Wisconsin, Milwaukee, WI.
  • Avigan D; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
  • Deol A; Karmanos Cancer Institute, Wayne State University, Detroit, MI.
  • Htut M; City of Hope Comprehensive Cancer Center, Duarte, CA.
  • Lesokhin A; Memorial Sloan Kettering Cancer Center, New York, NY.
  • Munshi NC; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • O'Donnell E; VA Boston Healthcare System, West Roxbury, MA.
  • Stewart AK; Massachusetts General Hospital, Harvard Medical School, Boston, MA.
  • Schecter JM; University Health Network and the Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Goldberg JD; Janssen R&D, Raritan, NJ.
  • Jackson CC; Janssen R&D, Raritan, NJ.
  • Yeh TM; Janssen R&D, Raritan, NJ.
  • Banerjee A; Janssen R&D, Raritan, NJ.
  • Allred A; Janssen R&D, Spring House, PA.
  • Zudaire E; Janssen R&D, Spring House, PA.
  • Deraedt W; Janssen R&D, Spring House, PA.
  • Olyslager Y; Janssen R&D, Beerse, Belgium.
  • Zhou C; Janssen R&D, Beerse, Belgium.
  • Pacaud L; Legend Biotech, Inc, Piscataway, NJ.
  • Madduri D; Legend Biotech, Inc, Piscataway, NJ.
  • Jakubowiak A; Janssen R&D, Raritan, NJ.
  • Lin Y; University of Chicago, Chicago, IL.
  • Jagannath S; Mayo Clinic, Rochester, MN.
J Clin Oncol ; 41(6): 1265-1274, 2023 02 20.
Article en En | MEDLINE | ID: mdl-35658469
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Receptores Quiméricos de Antígenos / Mieloma Múltiple Límite: Humans Idioma: En Revista: J Clin Oncol Año: 2023 Tipo del documento: Article País de afiliación: Canadá
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Receptores Quiméricos de Antígenos / Mieloma Múltiple Límite: Humans Idioma: En Revista: J Clin Oncol Año: 2023 Tipo del documento: Article País de afiliación: Canadá